Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of prussian blue in preparation of medicine for treating vascular restenosis

A technology of Prussian blue and restenosis, which is applied in the application field of medicine, can solve the problems such as the independent function of nanozymes that have not been studied, and achieve the effects of reducing migration and proliferation, alleviating long-term prognosis, and accelerating repair

Active Publication Date: 2020-08-25
SHANGHAI SIXTH PEOPLES HOSPITAL
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, few studies have addressed the independent role of nanozymes in the treatment of restenosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of prussian blue in preparation of medicine for treating vascular restenosis
  • Application of prussian blue in preparation of medicine for treating vascular restenosis
  • Application of prussian blue in preparation of medicine for treating vascular restenosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] (1) Add 2400mg of potassium ferricyanide and 5g of polyvinylpyrrolidone (PVP) into 60mL of 2M hydrochloric acid, and stir magnetically until a clear solution is obtained;

[0057] (2) Transfer the above-mentioned clear solution to an electric cooker, and react for 72 hours at a temperature of 200° C. and a pressure of 10 MPa;

[0058] (3) Take out and cool to room temperature, centrifuge, wash with deionized water several times, and freeze-dry to obtain Prussian blue nanoparticles with a size of 2-100 nm.

Embodiment 2

[0060] (1) Add 300 mg of potassium ferricyanide and 3 g of polyvinylpyrrolidone (PVP) to 50 mL of 2M hydrochloric acid, and stir magnetically until a clear solution is obtained;

[0061] (2) Transfer the above-mentioned clear solution to an electric cooker, and react for 48 hours at a temperature of 100° C. and a pressure of 20 MPa;

[0062] (3) Take out and cool to room temperature, centrifuge, wash with deionized water several times, and freeze-dry to obtain Prussian blue nanoparticles with a size of 2-100 nm.

Embodiment 3

[0064] Step A) Add 3960 mg of potassium ferricyanide and 35 g of polyvinylpyrrolidone (PVP) into 100 mL of 2M hydrochloric acid, and stir magnetically until a clear mixed solution is obtained;

[0065] Step B) Transfer the mixed solution to an oven at 80°C, age for 20 hours, take it out, cool to room temperature, centrifuge, wash with deionized water several times, dissolve in 50mL of 1.5M hydrochloric acid and set aside;

[0066] Step C) Transfer 20mL of the above solution to a hydrothermal kettle, place in an electric furnace, age at 120°C for 4h, take it out and cool to room temperature, centrifuge, wash with deionized water several times, and freeze-dry to obtain a pore size in the range of 3-20nm The inner size is 30-200nm mesoporous Prussian blue nanoparticles.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sizeaaaaaaaaaa
Specific surface areaaaaaaaaaaa
Sizeaaaaaaaaaa
Login to View More

Abstract

The invention provides an application of prussian blue in preparation of a medicine for treating vascular restenosis and a preparation method of prussian blue nanoparticles. At present, no special-effect medicine exists for vascular restenosis, so that the providing of the medicine with special effects for preventing and treating vascular restenosis has certain practical significance. The prussianblue provided by the invention can inhibit activation of a phosphorylation signal transduction element and a transcription activator 1 (p-STAT1), significantly targets macrophages, and polarizes themacrophages into M2, thereby effectively relieving long-term prognosis of restenosis. Besides, the prussian blue provided by the invention can significantly reduce pro-inflammatory cytokines, accelerate repair of endothelial cells and reduce migration and proliferation of vascular smooth muscle cells, thereby inhibiting the progress of restenosis.

Description

technical field [0001] The application relates to the application of Prussian blue, in particular, to the application of Prussian blue in the preparation of drugs for treating vascular restenosis. Background technique [0002] Cardiovascular disease is the leading cause of death in the world, with approximately 17.3 million deaths per year, including atherosclerosis and coronary heart disease. EIT has unique advantages such as less trauma, quick results, and a wide range of applications. However, one of the main complications after EIT is restenosis, which seriously affects the long-term prognosis and quality of life of patients. To date, restenosis remains a major drawback of EIT. The current clinical prevention and treatment methods mainly include antiplatelet and blood lipid-lowering drugs, which mainly focus on inhibiting thrombus formation and controlling blood lipid levels, which can reduce the incidence of restenosis. However, for patients with a history of surgery,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/26A61P9/10A61P7/02B82Y5/00
CPCA61K33/26A61P9/10A61P7/02B82Y5/00
Inventor 蔡晓军郑元义高维窦超然李跃华王燕胡兵
Owner SHANGHAI SIXTH PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com